Not Yet Recruiting PHASE4 INTERVENTIONAL 2-arm
NCT07426484
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
A Phase IV Master Protocol of Cosibelimab in Special Populations With Advanced Cutaneous Squamous Cell Carcinoma (CosiMaster)
Sponsor: Checkpoint Therapeutics, Inc.
Conditions
Cutaneous Squamous Cell Carcinoma Skin Cancer
Interventions
Cosibelimab Everolimus Prednisone Sirolimus
Updated 1 time since 2026 Last updated: Feb 20, 2026 Started: Jul 31, 2026 Primary completion: Dec 15, 2030 Completion: Dec 15, 2032
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07426484, this PHASE4 trial focuses on Cutaneous Squamous Cell Carcinoma and Skin Cancer and remains actively recruiting participants. Sponsored by Checkpoint Therapeutics, Inc., it has been updated 1 time since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE4
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Checkpoint Therapeutics, Inc.
- Dana-Farber Cancer Institute
Data source: Dana-Farber Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .